OPEN CFDA 12.420 ↗ Competitive Grant Hard ~100h to apply

DoW Breast Cancer, Clinical Research Extension Award

🏛 Dept. of the Army -- USAMRAA (DOD-AMRAA)

⏰ Deadline
Jul 8, 2026 in 37 days
📊 Total program funding
$15.4M
🎯 Expected awards
2 recipients
📍 Scope
National
📨 Letter of Intent
Yesrequired first

Can you apply?

This grant is for clinical research projects addressing breast cancer. Applicants must be researchers with institutional affiliations conducting human-subject research. The DoD prioritizes novel investigations that can extend preliminary findings toward clinical applications or trials. This is a federal award, so institutions must be accredited and capable of managing federal funding.

Eligible recipients typically include academic medical centers, teaching hospitals, research institutions, and military treatment facilities. Non-federal entities may partner with federal agencies. Organizations must comply with human subjects protections, institutional review boards (IRBs), and DoD security requirements.

Focus areas include clinical stage research, translational work approaching clinical testing, and investigations with clear potential for military or civilian benefit. Early-stage clinical trials and mechanism-of-disease studies are supported.

Eligible applicants
Check your eligibility — what type of organization are you?

This grant is for clinical research projects addressing breast cancer. Applicants must be researchers with institutional affiliations conducting human-subject research. The DoD prioritizes novel investigations that can extend preliminary findings toward clinical applications or trials. This is a federal award, so institutions must be accredited and capable of managing federal funding.

Eligible recipients typically include academic medical centers, teaching hospitals, research institutions, and military treatment facilities. Non-federal entities may partner with federal agencies. Organizations must comply with human subjects protections, institutional review boards (IRBs), and DoD security requirements.

Focus areas include clinical stage research, translational work approaching clinical testing, and investigations with clear potential for military or civilian benefit. Early-stage clinical trials and mechanism-of-disease studies are supported.

Program description

Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception.

Distinctive Features:

·        The research team must include two or more breast cancer consumer advocates.

·        This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and  Partnering PI) applications by the deadline may result in administrative withdrawal.

Who can apply

Eligible applicants

Details

This grant is for clinical research projects addressing breast cancer. Applicants must be researchers with institutional affiliations conducting human-subject research. The DoD prioritizes novel investigations that can extend preliminary findings toward clinical applications or trials. This is a federal award, so institutions must be accredited and capable of managing federal funding.

Eligible recipients typically include academic medical centers, teaching hospitals, research institutions, and military treatment facilities. Non-federal entities may partner with federal agencies. Organizations must comply with human subjects protections, institutional review boards (IRBs), and DoD security requirements.

Focus areas include clinical stage research, translational work approaching clinical testing, and investigations with clear potential for military or civilian benefit. Early-stage clinical trials and mechanism-of-disease studies are supported.

How to apply

Application links

Required documents

  • SF-424 (Federal Application Cover Sheet)
  • Project Narrative (Research Design and Methods)
  • Budget Narrative and Justification
  • Biographical Sketches (Key Personnel)
  • Letters of Support or Institutional Commitment
  • IRB Approval or Documentation of Human Subjects Plan
  • Military Relevance Statement (for DoD programs)

Program contact

  • 👤 Jamie Shortall Grant Officer
  • 📧 help@eBRAP.org
  • 📞 301-619-2393

Funding track record

Recent awards under CFDA 12.420 from the last 3 years — real organizations that won funding through this same program.

100
awards (3 yrs)
$4.3B
total funded
68
unique recipients
$42.7M
average award

Top 10 Largest Recent Awards

  1. $2,265,729,366
  2. $800,631,761
  3. $74,531,880
  4. $67,205,571
  5. $53,718,832
  6. $34,191,124
  7. $24,907,742
  8. $21,394,379
  9. $19,100,256
  10. $19,002,641

Top States by Funding

  • MD 10 awards $3,150.1M
  • NC 11 awards $132.3M
  • FL 8 awards $99.8M
  • CA 11 awards $99.3M
  • MA 7 awards $75.2M

Source: USAspending.gov — federal spending transparency. Data covers last 3 years.

Funding history

Annual funding for this program — Federal obligations (CFDA 12.420). How funding has trended year over year.

2024 $1,483,968,520
2025 $1,201,153,417

FAQ

Who can apply for this grant?

Researchers at accredited institutions with strong cancer research programs and IRB infrastructure. Military treatment facilities, academic medical centers, and qualifying research institutions are eligible.

What types of research does this award support?

Clinical-stage breast cancer research and translational studies moving toward clinical application. Applied research with human subjects is preferred over basic science.

When is the deadline?

The application opens May 4, 2026 and closes July 8, 2026. This is a fixed deadline with no extensions typical for DoD awards.

How competitive is this award?

DoD AMRAA awards are highly competitive. Success rates are typically 15-25% for clinical research. Strong preliminary data and clear clinical relevance are essential.

What is the typical funding range?

Awards vary by program but USAMRAA clinical extension awards typically provide $150,000–$500,000 total cost. Check the funding announcement for specific details.

💡 Tips for applicants

  • Lead with clear clinical relevance and military health connection where applicable. Reviewers want real-world impact.
  • Include strong preliminary data demonstrating feasibility. Weak pilot work leads to rejection.
  • Address potential barriers and risk mitigation early in your narrative. Reviewers expect honest assessment.
  • Budget must align with scope and timeline. Inflated or undersized budgets raise red flags.
  • Engage your IRB and compliance office before submission. Delayed approvals can cause missed deadlines.

⚠️ Common mistakes

Lack of preliminary data or weak justification for clinical relevance. Unrealistic timelines or budgets that don't match proposed scope. Failure to address human subjects protections and DoD security requirements upfront.

Similar grants

37 days left Jul 8, 2026
Apply →